Chargement...
Rouen, January 30, 2018 – Robocath, a company that conceives and develops cardiovascular robotic systems for the treatment of vascular diseases, announces today the creation of its medical advisory board including global experts and recognized leaders in interventional cardiology.
This committee will help define the clinical strategy of the company and more broadly contribute to the development of future generations of Robocath’s robotic system products.
Philippe Bencteux, president and founder of Robocath, said: “I’m particularly proud and pleased to welcome these key opinion leaders in interventional cardiology on to our medical advisory board (MAB). We all have a common vision regarding the future of medicine and the key role that robotic systems will play in the treatment of vascular diseases.”
This MAB will include the following experts: